Growing Incidences of Mental Disorders to Drive the Market
Injectable benzodiazepine drugs are administered as the first course of treatment with regards to mental disorders like depression, bipolar disorder, schizophrenia, dementia, anxiety disorder, autism.
The WHO, European Brain Council (EBC), and European College of Neuropsychopharmacology (ECNP) state that around 25% of the global population encounters mental disorders at least once in their lifetime.
As per NSDUH (National Survey on Drug Use and Health), in 2017, close to 46.6 million adults suffered from mental disorders (up by 1.5% in 2010) in the US. So, it could be inferred that 18-20% of the people in the US suffer from mental disorders, which are expected to account for the largest share of injectable benzodiazepines market in the forecast period.
As per the WHO, in the year 2017, around 35-40% of people in the EU were affected with mental disorders. Besides, as of 2015, increase in chronic depression resulted in higher absenteeism coupled with lower productivity at work. This lacuna had cost EU US$47.04 Billion Tn 2015.
On the other hand, India, in 2017, accounted for almost 15% of the global neurological, mental, and substance abuse disorders. In Asia-Pacific on the whole, more than 68% of the people are reported to have psychiatric disorders. This figure is expected to have Asia Pacific witness the highest growth rate in terms of injectable benzodiazepines.
As per the Anxiety and Depression Association of America, around 40 million adults of the US get affected by anxiety disorders every year. The medical fraternity states that the number of mental disorders would increase in the near future due to less attention being paid to self-talk.
All the facts mentioned above are expected to drive the injectable benzodiazepines market in the years to come.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Injectable benzodiazepine market is subject to fierce competition due to increasing adoption of generic injectables that prove to be cost-effective as compared to their branded counterparts. As per the Association of Accessible Medicines, branded drugs account for around 77% of the overall spending on prescriptions with merely 10% of those prescriptions getting filled.
Also, in the year 2017, generics saved close to US$ 265 billion through generics. These generics corresponded to treatment for hypertension, ulcer, cholesterol, and mental health.
Generic diazepam, midazolam, and lorazepam drugs are prescribed for seizures, insomnia, and anxiety. These generic medications are expected to boost the injectable benzodiazepines market in the forecast period.
Injectable Benzodiazepines Market Remains Consolidated
The inorganic modes of expansion include technology and distribution agreements, product improvement, and partnerships. These moves are expected to give an impetus to the market in the forecast period.
For instance – Xeris Pharmaceuticals, in Apr 2020, announced positive results out of their Phase 1b weight-based dosing study regarding diazepam intramuscular (IM) injection by using XeriSol technology.
In Dec, 2019, Eton Pharmaceuticals, Inc. announced commercial availability of Biorphen, an injectable benzodiazepine, for treating hypotension.
“SUBLOCADE”, a buprenorphine extended-release injection, is available in the US since Mar 2018 post approval from the US FDA for treating OUD (opioid use disorder).
Short-Acting Injectable Benzodiazepines Gaining Traction
Increasing demand for short-acting injectable benzodiazepines due to faster excretion and immediate action is resulting in higher level of supervised administration.
Panic disorders are reported to affect around 2.7% of the US population. Muscle spasm and alcohol withdrawal also call for short acting injectable benzodiazepine drugs.
Plus, feasible scenario relating to reimbursement has made these healthcare solutions affable. These measures are expected to upscale the market in the forecast period.
Covid-19 Crisis to Bolster the Market Short-Term
The outbreak of Covid-19 has raised uncertainties, which have led to the onset of various mental disorders.
For instance – in Italy, the basic concern revolves around managing family and children along with maintenance of own borders and spaces. Developing economies like Brazil aren’t getting any active support on the count of addressing mental illnesses. Professional institutions need to come into picture to address this.
In the UK, the worrisome issues include uncertain future, anxiety/stress, and getting bored. Over 63% of the population of the UK is concerned about what is exactly in store for them. This factor is bound to raise the number of cases relating to mental stress.
In countries like India, almost 33% of the entire population has admitted to have a pessimistic impact of Covid-19 as joblessness has set in. Those working on daily wages and also the ones in field jobs have already lost out on their source of income; which is making inroads for depression and anxiety.
In the US, over 30% of people have been reported to get mentally affected by Covid-19. As the future looks bleak, people are getting drawn towards being mentally blank. Along with the professional concerns, there are personal concerns like coping up with the corporate lifestyle. A vacuum is getting created involuntarily; which is adding to the stress.
The factors mentioned above are expected to drive the market for injectable benzodiazepines in the next few months.
Principal Consultant
There only a handful of patented injectable benzodiazepines that fall in the “branded” category. As such, procuring and developing the ingredients could prove to be complex. Besides, stringent regulations regarding quality assessment may hamper the market.
Also, intake of these drugs without proper medical advice may prove to be fatal. Since the year 2010, overdose of benzodiazepines has resulted in 6507 deaths in the US. Also, in Sweden, a study was conducted wherein it was revealed that benzodiazepines are the drugs with majority of forged prescriptions.
This factor also proves to be a restraint with respect to the growth of the market.
Injectable Benzodiazepines Market: Region-wise Analysis
North America and Europe hold the largest market share in injectable benzodiazepines mainly due to increasing adoption of generic injectable benzodiazepines. The US is expected to witness around 2.8% growth in 2020. In Latin America, anxiety and alcohol withdrawal symptoms are driving the market and expected to do so in the forecast period as well.
Asia Pacific is witnessing mass production of generic injectable benzodiazepines, which will facilitate its fastest growth rate in the upcoming period. Oceania and MEA are still in the growth phase.
The injectable benzodiazepines market is in the consolidation phase; with 15+ players involved in extensive research and capacity expansion to maintain a strong foothold in the market.
One such study was conducted in Sweden in Apr 2020 to look into the association between paternal and maternal mental disorders with risk of injuries in the adolescents and children. On the similar grounds, a new study by Boston Medical Center revealed that 1 in 3 people receive medication related to opioid use disorder, that too, within a year of non-fatal overdose of the same. Likewise, studies are being conducted across the globe to look for advantages of injectable benzodiazepines and their application in the broader scenario.
The key players in the injectable benzodiazepines market include:
Americas
Europe
Asia Pacific
*The list is not exhaustive, and only for representational purposes. Full competitive intelligence with SWOT analysis available in the report
Injectable Benzodiazepines: The Way Forward
The injectable benzodiazepines market, in the long run, shows optimism, with FMI’s analysis predicting a steady growth rate of 2.7% in the forecast period. Covid-19 pandemic will also see an upswing in the market for the subsequent months. At the same time, growing adoption of generic drugs is another factor providing traction to the market.
The manufacturers are needed to emphasize on production and cost management for addressing drug shortages and also reach out to wider geographies. Auto-injector technology, if put into practice, is bound to reach more number of people within no time. Also, players will have to collaborate with the governments to reform the regulations; so that more such drugs could be tabled.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
FMI’s study on the injectable benzodiazepines market offers information divided into three important segments— drug class, indication, time of action, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Drug Class
Time of Action
Indication
Distribution Channel
Region
The injectable benzodiazepines market is expected to grow at a 2.7% CAGR from 2022 to 2032
By 2022-end, injectable benzodiazepines sales are likely to reach US$ 274 Million
By 2032-end, injectable benzodiazepines sales are likely to reach US$ 356Million
Pfizer Inc., Akorn Inc, and Sun Pharmaceutical Industries Limited are some leading injectable benzodiazepines market vendors.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Market Background 4.1. Macro-Economic Factors 4.1.1. Global GDP Growth Outlook 4.1.2. Per Capita Healthcare Expenditure Outlook 4.1.3. Overall Psychoactive Drugs Market 4.2. Forecast Factors - Relevance & Impact 4.2.1. Increasing Incidence of Anxiety, Seizures, Insomnia 4.2.2. Increasing Usage as Anaesthesia 4.2.3. Dose Per Case 4.2.4. Treatment Cost 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 5. Market Context 5.1. Product Adoption / Usage Analysis By Indication 5.2. Disease Epidemiology, By Region 5.3. Regulatory Scenario 5.4. Reimbursement Landscape 5.5. Key Promotional Strategies, By Manufacturers 5.6. COVID19 Crisis Analysis 5.6.1. Current COVID19 Statistics and Probable Future Impact 5.6.2. Current GDP Projection and Probable Impact 5.6.3. COVID19 and Impact Analysis 5.6.3.1. Revenue By Class 5.6.3.2. Revenue By Country 5.6.4. 2020 Market Scenario 5.6.5. Quarter by Quarter Forecast 5.6.6. Projected recovery Quarter 5.6.7. Recovery Scenario – Short term, Midterm and Long Term Impact 6. Global Injectable Benzodiazepines Market Value (US$ Mn) Analysis 2015-2019 and Forecast, 2020-2030 6.1. Historical Market Value (US$ Mn) Analysis, 2015-2019 6.2. Current and Future Market Value (US$ Mn) Projections, 2020-2030 6.2.1. Y-o-Y Growth Trend Analysis 6.2.2. Opportunity Analysis, 2020-2030 7. Global Injectable Benzodiazepines Market Analysis 2015-2019 and Forecast 2020-2030, By Drug Class 7.1. Introduction / Key Findings 7.2. Historical Market Size (US$ Mn) Analysis By Drug Class , 2015–2019 7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Class , 2020-2030 7.3.1. Diazepam 7.3.2. Lorazepam 7.3.3. Midazolam 7.4. Market Attractiveness Analysis By Drug Class 8. Global Injectable Benzodiazepines Market Analysis 2015-2019 and Forecast 2020-2030, by Indication 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Mn) Analysis By Indication, 2014 - 2018 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2019 - 2030 8.3.1. Agitation & Aggression 8.3.2. Anxiety 8.3.3. Alcohol Withdrawal 8.3.4. Muscle Spasm 8.3.5. Seizures 8.3.6. Tetanus 8.3.7. Sedation 8.3.8. Local Anaesthesia 8.3.9. Insomnia 8.3.10. Status Epilepticus 8.4. Market Attractiveness Analysis By Indication 9. Global Injectable Benzodiazepines Market Analysis 2015-2019 and Forecast 2020-2030, By Time of Action 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Mn) Analysis By Time of Action, 2014 - 2018 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Time of Action, 2019 - 2030 9.3.1. Short Acting 9.3.2. Long Acting 9.4. Market Attractiveness Analysis By Time of Action 10. Global Injectable Benzodiazepines Market Analysis 2015-2019 and Forecast 2020-2030, by Distribution Channel 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2014 - 2018 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2019 - 2030 10.3.1. Hospital Pharmacies 10.3.2. Retail Pharmacies 10.3.3. Mail Order Pharmacies/Online Pharmacies 10.4. Market Attractiveness Analysis By Distribution Channel 11. Global Injectable Benzodiazepines Market Analysis 2015-2019 and Forecast 2020-2030, by Region 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Mn) Analysis By Region, 2015–2019 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2020-2030 11.3.1. North America 11.3.2. Latin America 11.3.3. Europe 11.3.4. East Asia 11.3.5. South Asia 11.3.6. Oceania 11.3.7. Middle East and Africa 11.4. Market Attractiveness Analysis By Region 12. North America Injectable Benzodiazepines Market Analysis 2015-2019 and Forecast 2020-2030 12.1. Introduction 12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2019 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030 12.3.1. By Country 12.3.1.1. U.S. 12.3.1.2. Canada 12.3.2. By Drug Class 12.3.3. By Indication 12.3.4. By Time of Action 12.3.5. By Distribution Channel 12.4. Market Attractiveness Analysis 12.5. Key Market Participants - Intensity Mapping 12.6. Drivers and Restraints - Impact Analysis 13. Latin America Injectable Benzodiazepines Market Analysis 2015-2019 and Forecast 2020-2030 13.1. Introduction 13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2019 13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030 13.3.1. By Country 13.3.1.1. Brazil 13.3.1.2. Mexico 13.3.1.3. Argentina 13.3.1.4. Rest of Latin America 13.3.2. By Drug Class 13.3.3. By Indication 13.3.4. By Time of Action 13.3.5. By Distribution Channel 13.4. Market Attractiveness Analysis 13.5. Key Market Participants - Intensity Mapping 13.6. Drivers and Restraints - Impact Analysis 14. Europe Injectable Benzodiazepines Market Analysis 2015-2019 and Forecast 2020-2030 14.1. Introduction 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2019 14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030 14.3.1. By Country 14.3.1.1. Germany 14.3.1.2. Italy 14.3.1.3. France 14.3.1.4. U.K. 14.3.1.5. Spain 14.3.1.6. BENELUX 14.3.1.7. Russia 14.3.1.8. Rest of Europe 14.3.2. By Drug Class 14.3.3. By Indication 14.3.4. By Time of Action 14.3.5. By Distribution Channel 14.4. Market Attractiveness Analysis 14.5. Key Market Participants - Intensity Mapping 14.6. Drivers and Restraints - Impact Analysis 15. South Asia Injectable Benzodiazepines Market Analysis 2015-2019 and Forecast 2020-2030 15.1. Introduction 15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2019 15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030 15.3.1. By Country 15.3.1.1. India 15.3.1.2. Thailand 15.3.1.3. Indonesia 15.3.1.4. Malaysia 15.3.1.5. Rest of South Asia 15.3.2. By Drug Class 15.3.3. By Indication 15.3.4. By Time of Action 15.3.5. By Distribution Channel 15.4. Market Attractiveness Analysis 15.5. Key Market Participants - Intensity Mapping 15.6. Drivers and Restraints - Impact Analysis 16. East Asia Injectable Benzodiazepines Market Analysis 2015-2019 and Forecast 2020-2030 16.1. Introduction 16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2019 16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030 16.3.1. By Country 16.3.1.1. China 16.3.1.2. Japan 16.3.1.3. South Korea 16.3.2. By Drug Class 16.3.3. By Indication 16.3.4. By Time of Action 16.3.5. By Distribution Channel 16.4. Market Attractiveness Analysis 16.5. Key Market Participants - Intensity Mapping 16.6. Drivers and Restraints - Impact Analysis 17. Oceania Injectable Benzodiazepines Market Analysis 2015-2019 and Forecast 2020-2030 17.1. Introduction 17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2019 17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030 17.3.1. By Country 17.3.1.1. Australia 17.3.1.2. New Zealand 17.3.2. By Drug Class 17.3.3. By Indication 17.3.4. By Time of Action 17.3.5. By Distribution Channel 17.4. Market Attractiveness Analysis 17.5. Key Market Participants - Intensity Mapping 17.6. Drivers and Restraints - Impact Analysis 18. Middle East and Africa Injectable Benzodiazepines Market Analysis 2015-2019 and Forecast 2020-2030 18.1. Introduction 18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2019 18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030 18.3.1. By Country 18.3.1.1. GCC Countries 18.3.1.2. Turkey 18.3.1.3. South Africa 18.3.1.4. Rest of Middle East and Africa 18.3.2. By Drug Class 18.3.3. By Indication 18.3.4. By Time of Action 18.3.5. By Distribution Channel 18.4. Market Attractiveness Analysis 18.5. Key Market Participants - Intensity Mapping 18.6. Drivers and Restraints - Impact Analysis 19. Key and Emerging Countries Injectable Benzodiazepines Market Analysis 2015-2019 and Forecast 2020-2030 19.1. Introduction 19.1.1. Market Value Proportion Analysis, By Key Countries 19.1.2. Global Vs. Country Growth Comparison 19.2. U.S. Injectable Benzodiazepines Market Analysis 19.2.1. By Drug Class 19.2.2. By Indication 19.2.3. By Time of Action 19.2.4. By Distribution Channel 19.3. Canada Injectable Benzodiazepines Market Analysis 19.3.1. By Drug Class 19.3.2. By Indication 19.3.3. By Time of Action 19.3.4. By Distribution Channel 19.4. Mexico Injectable Benzodiazepines Market Analysis 19.4.1. By Drug Class 19.4.2. By Indication 19.4.3. By Time of Action 19.4.4. By Distribution Channel 19.5. Brazil Injectable Benzodiazepines Market Analysis 19.5.1. By Drug Class 19.5.2. By Indication 19.5.3. By Time of Action 19.5.4. By Distribution Channel 19.6. U.K. Injectable Benzodiazepines Market Analysis 19.6.1. By Drug Class 19.6.2. By Indication 19.6.3. By Time of Action 19.6.4. By Distribution Channel 19.7. Germany Injectable Benzodiazepines Market Analysis 19.7.1. By Drug Class 19.7.2. By Indication 19.7.3. By Time of Action 19.7.4. By Distribution Channel 19.8. France Injectable Benzodiazepines Market Analysis 19.8.1. By Drug Class 19.8.2. By Indication 19.8.3. By Time of Action 19.8.4. By Distribution Channel 19.9. Italy Injectable Benzodiazepines Market Analysis 19.9.1. By Drug Class 19.9.2. By Indication 19.9.3. By Time of Action 19.9.4. By Distribution Channel 19.10. Spain Injectable Benzodiazepines Market Analysis 19.10.1. By Drug Class 19.10.2. By Indication 19.10.3. By Time of Action 19.10.4. By Distribution Channel 19.11. BENELUX Injectable Benzodiazepines Market Analysis 19.11.1. By Drug Class 19.11.2. By Indication 19.11.3. By Time of Action 19.11.4. By Distribution Channel 19.12. Russia Injectable Benzodiazepines Market Analysis 19.12.1. By Drug Class 19.12.2. By Indication 19.12.3. By Time of Action 19.12.4. By Distribution Channel 19.13. China Injectable Benzodiazepines Market Analysis 19.13.1. By Drug Class 19.13.2. By Indication 19.13.3. By Time of Action 19.13.4. By Distribution Channel 19.14. Japan Injectable Benzodiazepines Market Analysis 19.14.1. By Drug Class 19.14.2. By Indication 19.14.3. By Time of Action 19.14.4. By Distribution Channel 19.15. South Korea Injectable Benzodiazepines Market Analysis 19.15.1. By Drug Class 19.15.2. By Indication 19.15.3. By Time of Action 19.15.4. By Distribution Channel 19.16. India Injectable Benzodiazepines Market Analysis 19.16.1. By Drug Class 19.16.2. By Indication 19.16.3. By Time of Action 19.16.4. By Distribution Channel 19.17. ASEAN Injectable Benzodiazepines Market Analysis 19.17.1. By Drug Class 19.17.2. By Indication 19.17.3. By Time of Action 19.17.4. By Distribution Channel 19.18. Australia Injectable Benzodiazepines Market Analysis 19.18.1. By Drug Class 19.18.2. By Indication 19.18.3. By Time of Action 19.18.4. By Distribution Channel 19.19. New Zealand Injectable Benzodiazepines Market Analysis 19.19.1. By Drug Class 19.19.2. By Indication 19.19.3. By Time of Action 19.19.4. By Distribution Channel 19.20. GCC Countries Injectable Benzodiazepines Market Analysis 19.20.1. By Drug Class 19.20.2. By Indication 19.20.3. By Time of Action 19.20.4. By Distribution Channel 19.21. Turkey Injectable Benzodiazepines Market Analysis 19.21.1. By Drug Class 19.21.2. By Indication 19.21.3. By Time of Action 19.21.4. By Distribution Channel 19.22. South Africa Injectable Benzodiazepines Market Analysis 19.22.1. By Drug Class 19.22.2. By Indication 19.22.3. By Time of Action 19.22.4. By Distribution Channel 20. Market Structure Analysis 20.1. Market Analysis by Tier of Companies 20.2. Market Share Analysis of Top Players 20.3. Market Presence Analysis 20.3.1. Regional Footprint by Players 20.3.2. Product Foot print by Players 21. Competition Analysis 21.1. Competition Dashboard 21.2. Competition Benchmarking 21.3. Competition Deep Dive 21.3.1. Pfizer Inc. 21.3.1.1. Overview 21.3.1.2. Product Portfolio 21.3.1.3. Profitability by Market Segments (Product/Channel/Region) 21.3.1.4. Sales Footprint 21.3.1.5. Strategy Overview 21.3.1.5.1. Marketing Strategy 21.3.1.5.2. Product Strategy 21.3.1.5.3. Channel Strategy 21.3.2. Hikma Pharmaceuticals (West-Ward Pharmaceuticals) 21.3.2.1. Overview 21.3.2.2. Product Portfolio 21.3.2.3. Profitability by Market Segments (Product/Channel/Region) 21.3.2.4. Sales Footprint 21.3.2.5. Strategy Overview 21.3.2.5.1. Marketing Strategy 21.3.2.5.2. Product Strategy 21.3.2.5.3. Channel Strategy 21.3.3. Taj Pharmaceuticals Limited 21.3.3.1. Overview 21.3.3.2. Product Portfolio 21.3.3.3. Profitability by Market Segments (Product/Channel/Region) 21.3.3.4. Sales Footprint 21.3.3.5. Strategy Overview 21.3.3.5.1. Marketing Strategy 21.3.3.5.2. Product Strategy 21.3.3.5.3. Channel Strategy 21.3.4. Accord Healthcare Ltd 21.3.4.1. Overview 21.3.4.2. Product Portfolio 21.3.4.3. Profitability by Market Segments (Product/Channel/Region) 21.3.4.4. Sales Footprint 21.3.4.5. Strategy Overview 21.3.4.5.1. Marketing Strategy 21.3.4.5.2. Product Strategy 21.3.4.5.3. Channel Strategy 21.3.5. Dash Pharmaceuticals LLC 21.3.5.1. Overview 21.3.5.2. Product Portfolio 21.3.5.3. Profitability by Market Segments (Product/Channel/Region) 21.3.5.4. Sales Footprint 21.3.5.5. Strategy Overview 21.3.5.5.1. Marketing Strategy 21.3.5.5.2. Product Strategy 21.3.5.5.3. Channel Strategy 21.3.6. hameln pharma ltd 21.3.6.1. Overview 21.3.6.2. Product Portfolio 21.3.6.3. Profitability by Market Segments (Product/Channel/Region) 21.3.6.4. Sales Footprint 21.3.6.5. Strategy Overview 21.3.6.5.1. Marketing Strategy 21.3.6.5.2. Product Strategy 21.3.6.5.3. Channel Strategy 21.3.7. F. Hoffmann-La Roche Ltd 21.3.7.1. Overview 21.3.7.2. Product Portfolio 21.3.7.3. Profitability by Market Segments (Product/Channel/Region) 21.3.7.4. Sales Footprint 21.3.7.5. Strategy Overview 21.3.7.5.1. Marketing Strategy 21.3.7.5.2. Product Strategy 21.3.7.5.3. Channel Strategy 21.3.8. AdvaCare Pharma 21.3.8.1. Overview 21.3.8.2. Product Portfolio 21.3.8.3. Profitability by Market Segments (Product/Channel/Region) 21.3.8.4. Sales Footprint 21.3.8.5. Strategy Overview 21.3.8.5.1. Marketing Strategy 21.3.8.5.2. Product Strategy 21.3.8.5.3. Channel Strategy 21.3.9. Troy Laboratories Pty Ltd 21.3.9.1. Overview 21.3.9.2. Product Portfolio 21.3.9.3. Profitability by Market Segments (Product/Channel/Region) 21.3.9.4. Sales Footprint 21.3.9.5. Strategy Overview 21.3.9.5.1. Marketing Strategy 21.3.9.5.2. Product Strategy 21.3.9.5.3. Channel Strategy 21.3.10. Martin Dow 21.3.10.1. Overview 21.3.10.2. Product Portfolio 21.3.10.3. Profitability by Market Segments (Product/Channel/Region) 21.3.10.4. Sales Footprint 21.3.10.5. Strategy Overview 21.3.10.5.1. Marketing Strategy 21.3.10.5.2. Product Strategy 21.3.10.5.3. Channel Strategy 21.3.11. Sun Pharmaceutical Industries Limited 21.3.11.1. Overview 21.3.11.2. Product Portfolio 21.3.11.3. Profitability by Market Segments (Product/Channel/Region) 21.3.11.4. Sales Footprint 21.3.11.5. Strategy Overview 21.3.11.5.1. Marketing Strategy 21.3.11.5.2. Product Strategy 21.3.11.5.3. Channel Strategy 21.3.12. Intas Pharmaceuticals Limited 21.3.12.1. Overview 21.3.12.2. Product Portfolio 21.3.12.3. Profitability by Market Segments (Product/Channel/Region) 21.3.12.4. Sales Footprint 21.3.12.5. Strategy Overview 21.3.12.5.1. Marketing Strategy 21.3.12.5.2. Product Strategy 21.3.12.5.3. Channel Strategy 21.3.13. Teva Pharmaceutical Industries Ltd. (Actavis Pharma, Inc.) 21.3.13.1. Overview 21.3.13.2. Product Portfolio 21.3.13.3. Profitability by Market Segments (Product/Channel/Region) 21.3.13.4. Sales Footprint 21.3.13.5. Strategy Overview 21.3.13.5.1. Marketing Strategy 21.3.13.5.2. Product Strategy 21.3.13.5.3. Channel Strategy 21.3.14. Akorn Inc 21.3.14.1. Overview 21.3.14.2. Product Portfolio 21.3.14.3. Profitability by Market Segments (Product/Channel/Region) 21.3.14.4. Sales Footprint 21.3.14.5. Strategy Overview 21.3.14.5.1. Marketing Strategy 21.3.14.5.2. Product Strategy 21.3.14.5.3. Channel Strategy 22. Assumptions and Acronyms Used 23. Research Methodology
Explore Healthcare Insights
View Reports
Injectable Benzodiazepine Market
